Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
Causal associations have been established between dysregulated ribosome biogenesis and cancer. In this Opinion article, the authors highlight emerging mechanistic data on the molecular basis of ribosomes in cancer and offer their perspective on how these advances present therapeutic opportunities.
Emerging data indicate that exercise modulates cancer biology and disease outcomes; however, the molecular mechanisms are poorly established. In this Opinion article, the authors speculate on how exercise might reprogramme the tumour microenvironment to influence cancer hallmarks.
In this Opinion article, Baslan and Hicks discuss how single-cell sequencing could be used to advance our understanding of tumour biology and genetics, in addition to translational applications in the clinic.
This Opinion article discusses recent studies that have provided new insights into the mechanisms of common fragile site instability and the resulting genomic effects, which include the generation of focal copy number alterations that affect the genomic landscape of many cancers.
In this Opinion article, Schneideret al. outline tissue- and cell type-specific differences in tumorigenesis and the organization of oncogenic signalling pathways, and discuss the implications of our understanding of tissue context on molecularly targeted therapy and clinical trial design.
This Opinion article focuses on the trends and progress being made in identifying protein biomarker signatures of clinical utility in cancer using, in particular, blood-based proteomics.
This Opinion article discusses progress and challenges in using patient-derived xenograft (PDX) models in cancer precision medicine. It is primarily co-authored by members of the EurOPDX Consortium and as such highlights the merits of shared PDX resources.